Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05708755 · ClinicalTrials.gov registry record · Phase 2
CMV Immunity Monitoring in Lung Transplant Recipients
A Phase 2 study of Lung Transplant; Complications, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT05708755 is a Phase 2 study of Lung Transplant; Complications that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 50 participants, below the 568-participant average among 6 other Lung Transplant; Complications trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05708755, a Phase 2 study of Lung Transplant; Complications, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the safety and feasibility of using a laboratory test to guide duration of antiviral prophylaxis with valganciclovir (medication used to prevent viral infections) after lung transplant. The laboratory test, inSIGHT™ CMV T Cell Immunity Panel, measures patients' immune response to a common viral infection known as cytomegalovirus (CMV). The goal of this study will be to safely decrease how long patients need to take valganciclovir based on the results of the CMV T Cell Immunity Panel.
Conditions Studied
Interventions
- DEVICE Cytomegalovirus T Cell Immunity Panel (CMV-TCIP)
- DIAGNOSTIC_TEST Donor-Derived Cell-Free DNA (dd-cfDNA) Assay
- DRUG Valganciclovir
Study Locations (1)
New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-09-13 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05708755
The ClinicalTrials.gov registry entry for NCT05708755 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 568-participant average among 6 other Lung Transplant; Complications trials with a reported enrollment target (91% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Transplant; Complications appearing as the primary indexed condition, and to 3 interventions - of which Cytomegalovirus T Cell Immunity Panel (CMV-TCIP) is the first listed.
NCT05708755 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05708755 about?
NCT05708755 is a clinical study titled "CMV Immunity Monitoring in Lung Transplant Recipients". The purpose of this study is to determine the safety and feasibility of using a laboratory test to guide duration of antiviral prophylaxis with valganciclovir (medication used to prevent viral infections) after lung transplant. The laboratory test, inSIGHT™ CMV T Cell Immunity Panel, measures patien...
What is the current status of trial NCT05708755?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2024-09-13. Estimated completion is 2026-09.
What conditions does trial NCT05708755 study?
This clinical trial studies the following conditions: Lung Transplant; Complications.
What interventions are being tested in trial NCT05708755?
The interventions under investigation include: Cytomegalovirus T Cell Immunity Panel (CMV-TCIP) (DEVICE), Donor-Derived Cell-Free DNA (dd-cfDNA) Assay (DIAGNOSTIC_TEST), Valganciclovir (DRUG).
Who is sponsoring clinical trial NCT05708755?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05708755 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Transplant; Complications
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Early Use of Long-acting Tacrolimus in Lung Transplant Recipients
RECRUITING · Early Phase 1
-
Prospective Multicenter Research on Donor and Recipient Management Strategies to Improve Lung Transplant Outcomes
RECRUITING
-
Implementation of a Clinical Tool to Improve Waitlist Mortality in Patients With Cystic Fibrosis
ACTIVE NOT RECRUITING · NA
-
AlloSure Lung Assessment and Metagenomics Outcomes Study
ACTIVE NOT RECRUITING
-
Preventing Rehospitalization in Lung Transplant Recipients Utilizing mHealth
COMPLETED · NA
-
Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.